Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tezspire
Pharma
FDA approves 2nd indication for Amgen, AstraZeneca's Tezspire
The FDA has endorsed Amgen and AstraZeneca’s Tezspire for patients age 12 and older with chronic rhinosinusitis with nasal polyps.
Kevin Dunleavy
Oct 17, 2025 5:12pm
Amgen, AZ Tezspire sinusitis data invite 'best-in-disease' talk
Mar 3, 2025 11:52am
Amgen, AZ's Tezspire excels in phase 3 rhinosinusitis trial
Nov 8, 2024 3:31pm
Improved access helps Amgen's Tepezza to a sales increase
Aug 7, 2024 8:35am
Dupixent data enhance Sanofi, Regeneron's pursuit of COPD nod
May 20, 2024 2:24pm
Amgen, AZ see Tezspire's promise in COPD despite trial miss
May 20, 2024 10:16am
